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Abstract 
Contact lenses (CLs) designed to deliver medication gradually to the eye are being developed 
and investigated for the use in ocular drug delivery. The aim of the current research is to 
determine patients’ acceptance of the use of lenses for ocular drug delivery. In addition, the 
study aimed to seek the views and perceptions of healthcare professionals (HCPs) on CLs as a 
method of ocular drug delivery and whether it will be prescribed to treat ocular conditions.  
This was a cross-sectional survey targeted at patients and HCPs. Two separate 
questionnaires were created with open-closed ended and multiple response questions, 
gauging the perceptions and acceptance of CLs as drug delivery tool. The patients’ survey was 
distributed in  John Radcliffe (JR), Oxford and Moorfields eye hospital (MEH), London, UK. The 
HCPs’ questionnaire was manually distributed and was also devised on Survey Monkey and 
sent by email to ophthalmologists, optometrists, opticians, GPs and hospital and community 
pharmacists. The data were analysed using SPSS statistical software and Excel. 
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Over 60% (92/151) of patients would accept the use of CLs for their ocular treatment with the 
highest acceptance being reported by patients in the age group of 30-49 years old. The most 
frequently used conventional treatment formulation was eye drops as indicated by 87% 
(131/151) of the responses. More than half of eye drop users (57%,75/131) indicated that they 
would accept using CLs expecting them to reduce the frequency of application of the medicine 
and be less time consuming. Interestingly, half of HCPs were not aware of CLs as an ocular drug 
delivery method; nevertheless, a total of 65 HCPs out of the 112 surveyed  stated that they 
would prescribe/dispense CLs to treat ocular disease. 
Key words: contact lenses (CLs), drug delivery, questionnaire, acceptance, health care 
professionals (HCPs) 
Introduction 
Conventional ocular formulations such as eye drops, ointments and gels are the most 
commonly used ocular delivery formulations. However, there are numerous drawbacks and 
limitations associated with these dosage forms together with the physiological barriers 
presented by the eye (1). Physiological barriers include blinking and washing out drugs by tear 
fluid, nasolacrimal drainage and impermeability of the cornea. Studies revealed a high 
prevalence of non-compliance and an inability to adequately instil a drop into the eye (2).  The 
problem gets more prominent with elderly or patients with arthritis as they could not generate 
enough force to squeeze the eye drop bottle (2). Thus, drug delivery to the eye can be a 
challenge and consequently new ocular delivery systems have been developed to overcome 
these issues, namely; nanomicelles, nanoparticles, liposomes, implants, in-situ gelling systems 
and CLs. CLs loaded with drugs have been developed using several active ingredients such as 
prednisolone (3), β-blockers (4), antihistamines (5) and antimicrobials (6). Poly- hydroxy 
methyl methacrylate (pHEMA) CLs allowed higher ocular bioavailability for dexamethasone 
compared to eye drops (7). A system of hydrogel formulation using β-cyclodextrin grafted onto 
pHEMA-coglycidyl methacrylate was found to enhance diclofenac loading by 1300% and 
sustain drug release for two weeks (8). A study conducted by Hu et al.  demonstrated that 
modified functional hydrogel CLs loaded with puerarin had a better efficacy in lowering 
intraocular tension compared to commercially available eye drops (9). Dual therapy CLs for 
glaucoma were developed recently, and composed of 20% (w/w) vitamin E, timolol and 
dorzolamide. The lenses were found to be more effective in reducing intraocular pressure 
compared to eye drops (10). 
Drug loaded CLs can be used as a potential dosage form, subject to patients’ acceptance and 
willingness to use them.  An example that reflects the importance of consulting patients’ views 
prior to marketing is Exubera™ inhaler. It was marketed by Pfizer as a device for insulin lung 
delivery to replace short acting prandial insulin. It was withdrawn after a short period from the 
market because the product was not optimised according to the patients’ desires (11). Thus, it 
is important to deeply investigate patients’ views about a novel device before large-scale 
manufacturing and marketing.  
Therefore, the aim of the current study is to assess patients’ receptiveness and acceptance of 
this new ocular delivery approach. In addition, this study sought the feedback and perceptions 
of HCPs towards the use of medicated CLs as drug delivery systems. The aims can be translated 
into the following objectives; to gather information about the most common eye disease 
diagnosed and dosage form prescribed or used for treatment of eye conditions, to study the 
reasons why patients/HCPs might or might not be in favour of using CLs and to understand the 
factors that may influence the participants’ decision in using/prescribing or dispensing CLs. 
The outcomes will enable formulation scientists to understand the challenges that face the use 
of medicated CLs and eventually establish whether prescribers would prescribe/dispense CLs 
for ocular drug delivery. This will enable interested stakeholders to gain insight into current 
and future trends in the applications of CLs. 
METHODS 
A. Study design for patients’ survey 
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Questionnaires were used as the data collection tool for the study. The patients’ survey was 
made of 22 questions of different format. In total, there were 22 questions; twelve multiple 
choice questions, six dichotomous questions, two numerical rating scale questions, and two 
questions were open ended. The questions contained items on demographic characteristics, 
current ocular treatment, use of CLs and acceptance of CL use. The inclusion criteria were 
patients over 18 years old who suffer from an ocular condition. Responses were collected from 
both the John Radcliffe Hospital (JR) and Moorfields eye hospital (MEH), where the 
questionnaires were handed as hardcopies to patients who were willing to participate.  A 
softcopy of the questionnaire was generated on a Google document and the link together with 
the participant information sheet were emailed to a list of patients who opted to take part in 
the research when approached by a pharmacist member of staff at MEH.. Consent was implied 
by completion of the questionnaire. The questionnaires were collected between March and 
September 2016. 
B. Study design for Healthcare professionals’ survey 
The survey for HCPs included twenty questions; fourteen of the questions were multiple 
choices, three were dichotomous questions and three were open-ended questions. The survey 
sought HCPS’ common prescribed treatments and the most common conditions they treat, 
their views on patients’ perceptions on current treatments, and finally their perceptions on 
medicated CLs; the benefits and problems of their use and whether they would prescribe 
them. In addition, two questions were included to identify the exact profession of the HCP and 
their years of experience.  
HCPs were either sent a Survey Monkey link to the questionnaire or given a hard copy to fill 
out. Another way that data were collected was by circulating the Survey Monkey link on the 
MEH network. Furthermore, the link was posted on an optometrist LinkedIn account. Lastly, a 
LinkedIn profile was produced in order to access ophthalmologists’ email addresses, and 
emails containing the survey monkey link were sent to them. Responses were collected in the 
period from March to September 2016. The HCPs who took part in filling the questionnaire 
were ophthalmologists from MEH, optometrists, opticians, GPs, hospital pharmacists and 
community pharmacists working in Shepherd’s Bush and Croydon, London, UK. 
C. Data analysis 
The responses of both questionnaires were coded and entered into SPSS for Windows, version 
23 (International Business Machines (IBM), New York, USA). Two researchers reviewed the 
data for quality assurance. As the data were non-normally distributed and ordinal in nature, 
chi-square test was used to identify any associations between responses. Sub-analyses were 
performed by respondents’ eye disease, formulation currently used, gender, age and 
awareness of current development in ocular drug delivery. The statistical values reported are 
a comparison between one group against the other. An a priori level of <0.05 (P < 0.05) was 
set as significant. Excel was used to generate graphs. All data remained anonymous throughout 
the research in order to protect participant confidentiality.  
RESULTS 
A. Patient Survey 
I. Sample characteristics 
The questionnaire was distributed to 42 patients at the JR where 24 responses were collected 
leading to a response rate of 57%. MEH patients were approached through Moorfields staff by 
email so it is difficult to determine the response rate as the email was distributed through a 
mass circulation. The final number of patient participants in the study was 151. The 
demographics of the patients are summarised in Table 1. 
Table 1: Demographics of participating patients and HCPs and their acceptance of using CLs 
  Patients demographics 
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Gender Number of 
patients  
(N=149), (%) 
Acceptance of medicated CLs  
n, (%) 
 
Male 57 (38%) 38/57 (67%) 
Female 92 (62%) 53/92 (58%) 
Age Number of 
patients  
(N=150), (%) 
Acceptance of medicated CLs 
n, (%) 
 
18-29                             28 (19 %) 20/28 (71%) 
30-49                             41(27%) 31/41 (76%) 
 50-69                             69 (46%) 36/69 (52 %) 
70+                               
 
12 (8%) 
 
5/12 (42%) 
  HCPs demographics 
Occupation Number of 
HCPs  
(N=112), (%) 
Number of HCPs willing to 
prescribe/dispense medicated CLs  
n, (%) 
Community pharmacist   34 (30%) 23/34 (68%) 
Hospital pharmacist 14 (13%) 6/14 (43%) 
General Practitioner  10 (9%) 6/10 (60%) 
Consultant Ophthalmic 
surgeon  
6 (5%) 5/6 (83%) 
Optician/Contact Lens 
Optician 
5 (4%) 4/5 (80%) 
Consultant 
Ophthalmologist  
5 (4%) 2/5 (40%) 
Optometrist 23 (21%)  12/23 (52%) 
Others 15 (13%) 7/15 (47%) 
 
 
II. Patients’ perceptions   
Overall 92 (61 %) of patients said they would consider using CLs for drug delivery. More 
females claimed they would use CLs than males but the difference was not statistically 
significant (p=0.31). The highest acceptance percentage was reported by 30-49 years old 
(76%). This was statistically significant (p=0.05) (Table 1). Regarding the current formulation of 
ocular treatment, the data collected showed that 87% (n=131) of the total participants are 
using eye drops either alone or with other form of ocular medications and 36% (n=54) are 
using eye ointments. Patients who use eye drops were more likely to accept CLs as a treatment 
option (p =0.03) (Table2). 
Table 1: Patients’ Current treatment formulation stratiﬁed by acceptance of contact lenses 
use. 
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Current treatment 
formulation 
Number of 
responses 
 (N=151) 
Acceptance of 
medicated CLs 
n, (%) 
P value 
Eye drops 131  75/131 (57%)  0.03* 
Eye ointment 54 32/54 (59%) 0.80 
Eye gel 33  20/33 (61%) 0.43 
Tablets 43  27/43 (63%) 0.45 
Eye inserts 12  8/12 (67%) 0.24 
Injections 10 9/10 (90%) 0.06 
 
P is the calculated probability and was reported as significant difference when P<0.05. Chi-
squared test was performed by comparing CLs’ acceptance per patients’ current treatment 
formulation against the acceptance of those using other formulation. *Statistically significant 
at 95% confidence level. 
The questionnaire included a question about the duration of patient’s current ocular 
treatment. Around 80 patients indicated that their eye drop usage was long term; 59% 
(n=47/80) of long term users indicated they would use CLs. When patients were asked about 
the difficulty in using their current medication, 25 claimed to face difficulty when applying their 
medication with half of them (n=13) stating that they are willing to use medicated CLs as an 
alternative. 
Table 3 shows the prevalence of eye conditions among of the surveyed patients, whereby 
patients were allowed to choose more than one option. It was found that just above half of the 
patients who had age-related long-term conditions such as glaucoma and cataract would 
consider using CLs for treatment.  There was no statistical association between the condition 
suffered and acceptance of CLs use (Table 3). 
Table 2: Patients’ current condition stratiﬁed by acceptance of contact lenses use 
Patient current 
condition 
Number of responses 
(N= 151) 
 Acceptance of 
medicated CLs 
n, (%) 
P value 
Dry eyes 60  35/60 (58%) 0.65 
Glaucoma 48  26/48 (54%) 0.14 
Cataracts 37  
 
19/37 (51%) 0.16 
Inflammation post-
surgery 
   18  11/18 (61%) 0.85 
Conjunctivitis  15  7/15 (47%) 0.18 
Age-Related Macular 
Degeneration* 
10  7/10 (70%)  
Keratoconus* 6  3/6 (50%) 
Stys* 5  3/5 (60%) 
Blepharitis* 5    5/5 (100%) 
TED*  5  1/5 (20%) 
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Acanthamoeba 
Keratitis (AK) *  
4  3/4 (75%) 
Uveitis* 4  3/4 (75%) 
Sjogrens* 4  2/4 (50%) 
Others * 11    5/11 (46%) 
  
P is the calculated probability and was reported as significant difference when P<0.05. Chi-
squared test was performed by comparing CLs’ acceptance per patients’ current condition 
against those with other conditions. *Chi-squared test was not performed as the sample size 
was too small.  The “others” category included; 3 patients with blepharospasm, 3 patients with 
retinopathy, 2 patients with subconjunctival haemorrhage and 1 patient with either 
episcleritis, macular oedema or Usher syndrome. The patient’s acceptance of medicated CLs 
was indicated as 2/3, 2/3, 1/2 and 0/1, respectively. 
 
The questionnaire also enquired about patient satisfaction with their current treatment.  A 
total of 136 patients answered the question with yes or no. Over two thirds of patients; 69% 
(94/136) patients were satisfied with their treatment whereas 42 (31%) were not satisfied. Of 
those who were satisfied, 53 % (50/94) of patients stated they would be willing to use CLs for 
treatment. On the other hand, 81% (34/42) of patients who were not satisfied claimed they 
would use medicated CLs. There was a statistical significance association between treatment 
dissatisfaction and the acceptance to use CLs (P=0.012). Further analysis on the dissatisfied 
patients showed that 90% (38/42) of those patients were using eye drops and mostly suffered 
from dry eyes (43% (18/42)). 
Furthermore, the study assessed patients’ awareness of current developments in eye 
medication delivery. Only 22% (33/151) of patients were aware of new developments and 61% 
(20/33) of those patients stated to indicate an acceptance to the use of CLs. However, there 
was no statistically significant association between having knowledge on developments of 
ocular drug delivery and the acceptance of using lenses for treatment (P=0.77). 
In total, 24% (36/151) of the patients questioned were already CLs users and 86 % (31/36) of 
them accepted the use of CLs for treatment. Patients who have not used CLs before and did 
not want to use them indicated “worried about damaging my eye” or/and ”I will have problems 
with applying CLs” as the main reasons for lack of acceptance (Figure 1).  
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Figure 1:  The views of non-CLs users who would not accept the use of CLs (n=50) for treatment. 
A multiple-choice question was used to understand the reason why non-CLs wearer would not 
want to use CLs for drug delivery. 
A multiple-choice question enquired about the reason for potential use of CLs, participants 
(n=92) could choose more than one option and add their own views. Nearly two thirds of 
participants (n=64) explained the reason for accepting the use of CLs as ‘reduced applications 
of medication’ followed by 46 patients selecting ‘less time consuming’ (Figure 2).  
 
Figure 2: Reasons for accepting medicated CLs use by patients. A multiple-choice question 
was used to ask about the reason for opting to use of CLs for drug delivery (n=92). 
 
B. Health care professionals 
i. Sample characteristics 
Hundred and twelve HCPs took part in the current study. Table 1 shows the response rate per 
the occupation of the participant. As illustrated in Figure 3, 7% (n=8) of practitioners had less  
0
5
10
15
20
25
30
Worried
about
damaging  my
eyes
I don't know
enough
information
I will have
problems with
applying
contact lenses
Easier to use
eye drops
Too hard to
store and
clean
Bad
experience
Nu
m
be
r o
f p
at
ie
nt
s
Patient response
0
10
20
30
40
50
60
70
Reduced
applications
of
medication
Less time
consuming
Medication
is better
taken into
the eye
You are
already a
contact lens
user
Contact
lenses don't
have a bad
taste like
eye drops
Intersted in
new
treatments
Less
invasive
than
injections
Like novel
ideas that
can reduce
hassle to
paient
Willing to
try new
methods of
treatment
Nu
m
be
r o
f P
at
ie
nt
s 
9 
 
than 1 year experience, 34% (n=38) have 1 to 5 years of experience, 20% (n=22) have worked 
for 6 to 10 years and lastly 39% (n=44) had more than 10 years of experience. 
 
 
Figure 3: Years of experience versus acceptance to prescribe/dispense medicated CLs (N=112) 
 
The most frequent eye condition HCPs deal with is conjunctivitis (80%), followed by blepharitis 
(60%) (Table 4). The vast majority of HCPs (83%) normally prescribe eye drops followed by eye 
ointments. 
Table 3 4: The most common eye conditions HCPs deal with and eye formulation HCPs 
commonly prescribe/dispense. Multiple choice question was used and participants were able 
to select more than one answer.  
Eye conditions 
Number of responses 
 (N=111), (%) 
Conjunctivitis  
(Allergic or Infective) 
89 (80%) 
 
Blepharitis 67 (60%)  
Glaucoma 58 (52%)  
Cataracts 58 (52%)  
Age-Related Macular Degeneration 35 (32%)  
Uveitis 23 (21%)  
Subconjunctival haemorrhage 22 (20%)  
Others 13 (12%)  
Formulation Number of responses  (N=112), (%) 
Eye drops 93 (83%) 
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Eye Ointments/Creams 7 (6 %) 
Eye gels 6 (5%) 
Ocular inserts 0 (0%) 
Other  6 (5%) 
 
Most HCPs (81%) believed that eye drops are the patients’ preferred treatment method. A 
follow up question was posed to understand why HCPs prescribe or dispense the preferred 
formulation, 60% contributed that to their effectiveness and 55% to them being patient 
friendly. 
Half of HCPs (50%) believe that patients favour forms which are easy to administer while 21% 
believe that they favour treatments which are convenient. HCPs were asked about the 
problems that patients may face in relation to their current ocular medication and the 
response provided included; difficulty in administering the medication, the multiple 
applications needed and forgetfulness that negatively impacts their compliance. More than 
half of HCPs (54%) claimed that some patients need to re-visit the clinic or even the Accident 
and Emergency (A&E) for cases relating to ocular diseases mainly due to non- compliance  
(54%), ineffective treatment (23%) or wrong diagnosis (8%). HCPs were asked if they have 
heard of the concept of using CLs to deliver drugs to the eye prior to the current survey; nearly 
half of participants (51%) had not hear about them and 23/57 (40%) of those who did not have 
prior knowledge were not willing to prescribe/dispense medicated CLs. HCPs who said they 
know about medicated CLs were 55 and 62% of them  (34/55) were willing to 
prescribe/dispense them.  
Overall, 58% (65/112) of HCPs would be willing to prescribe/dispense medicated CLs. The 
majority of HCPs (71 %) agreed that having new formulation for ocular drug delivery such as 
CLs is good as it provides more options for ocular treatment. Whereas, 13% of practitioners 
found available treatments are sufficient (Table 5). 
Table 4: Views of HCPs about the use of CLs as an alternative form of ocular drug 
delivery. A multiple-choice question was used and participants were asked to select 
one answer only (N=112). 
Answer Options Number of responses 
(N=112), (%) 
Preferable to have another ocular treatment option for 
prescribers to select from based on patient needs/conditions 
to be treated 
80 (71%) 
Current ocular drug delivery methods, like eye drops, are 
sufficient 
14 (13%) 
It is necessary to use CLs as an alternative form of ocular drug 
delivery 
11 (10%) 
Others 7 (6%) 
 
Figure 4 displays the expectations of HCPs from the use of CLs for drug delivery. Most 
practitioners (81%) expected that the benefit will be longer duration of action and so reduced 
frequency of administration, while 50% expected better efficacy compared to conventional 
ocular drugs. Additionally, 46% of practitioners believed that there will be increased regimen 
adherence with CLs use.  
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Figure 4: HCPs views about the benefits of medicated CLs. HCPs were asked about the 
benefits of using CLs to treat ocular diseases/conditions.  Participants were able to  select 
more than one answer (N=112). 
Based on HCPs’ opinions, the risks and challenges of  medicated CLs are the likelihood of eye 
infections and inflammation (74%) and high costs (69%). Additionally, 58% of HCPs speculated 
challenges in counselling patients on the use of medicated CLs (Table 6). The ‘Other’ responses 
given were “Can be hard to administer for certain people” or “Unsure how it would maintain 
its sterility if the patient touches the CL to put it into the eye”. 
Table 5: The risks and challenges of using CLs as a drug delivery tool. A multiple-choice question 
was used and participants were able to  select more than one answer (N=111).  
Answer Options Number of 
responses 
(N=111), (%) 
Eye infections/inflammations 82 (74%) 
Expensive when compared to conventional ocular drugs like eye drops 77 (69%) 
Challenges in counselling patients on its use 64 (58%) 
Less patient adherence 27 (24%) 
Other  8 (7%) 
 
In spite of the risks and challenges associated with the use of CLs, 59% of practitioners felt that 
the benefits of CLs for drug delivery outweigh the risks of it, whereas 41% of HCPs disagreed.  
Discussion 
Despite the progress in CLs for ocular drug delivery, to our knowledge no studies have assessed 
patients’ acceptance and HCPs’ perceptions of this novel route of medicine administration to 
the eye. This study aimed to highlight the factors that would influence the acceptance of CLs 
which included treatment duration, treatment type, condition, demographics and awareness 
of formulation developments. 
The most common eye conditions found in our sample were dry eyes, glaucoma, and cataract 
which are normally known as age-related eye diseases. From the patients’ survey, eye drops 
were listed as the most used ocular dosage form which is consistent with previous findings 
where eye drops accounted for 90% of marketed ophthalmic formulations (1).  
According to HCPs, conjunctivitis is the most commonly seen ocular disease as indicated by 
80% of the responses, which is in correspondence with a study by Mcdonnell  (12). The study 
found that two out of four of the most common ocular diagnoses were bacterial and allergic 
conjunctivitis. The reason for conjunctivitis being rather common in this study is possibly due 
to the high number of community/hospital pharmacists in the sample population, where 
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infective conjunctivitis is commonly treated by pharmacists using over the counter medication. 
For treatment of these conditions, 83% of practitioners prescribe eye drops and 81% of all 
HCPs feel that patients prefer them over other ocular formulations. Patient preference for eye 
drops, according to the HCPs’ point of view, is mainly due to them being easy to administer. 
However, this contradicts their view that the main problem with current ocular medication, 
eye drops mainly, is the difficulty to administer them. Although eye drops are quite easy to 
administer when compared to other currently available forms, patients are still finding 
difficulties with their use. The problems that comes with eye drops cannot easily be overcome 
by education or counselling since the issues are mainly due to trying to aim the bottle into the 
centre of the eye, a fear of applying or reflex blinking (2). There was a statistically significant 
association between the use of eye drops by the patients and their acceptance to use CLs 
(P=0.03). Gender did not impact the patients’ acceptance of medicated CLs (P=0.31) 
meanwhile the age did as participants within the 30-49 years age group (P=0.03) were more 
open to using the new treatment. On the other hand, more than half of eye drops prescribers 
(58%) are willing to prescribe medicated CLs.  
The study revealed that 31% of patients were dissatisfied with their treatment and most of 
them (n=38) were using eye drops, 34 of these patients were open to the use of medicated 
CLs. A previous study (13) explained that patients tend to use alternative methods when they 
are dissatisfied with their conventional treatment which is not providing them with the 
expected results. Similarly, patients dissatisfied with their eye drops may welcome the novel 
technology.  
Both HCPs and patients explained that the main reason for accepting CLs as ”reduced 
applications of medication” (Figures 2, 4). Multiple doses of any medication may reduce 
compliance which can be combatted by a long acting medication or by replacing eye drops with 
medicated CLs or inserts. Studies have revealed that application of eye drops more than once 
a day can reduce patients’ compliance  to the dosage regime in patients with glaucoma (14). 
This correlates with our findings as patients who showed acceptance for CLs were seeking less 
frequent dosing and eventually better regimen adherence. Besides, over 75% of the HCPs 
agreed that CLs will offer a longer duration of action, hence greater compliance and better 
efficacy. Moreover, few studies suggested that elderly patients have lower compliance rate 
than younger patients (15) so the use of CLs with its advantageous longer duration and less 
frequent dosing would possibly improve their  compliance.  
Over 86% of the patients who currently wear lenses chose to use them for treatment which 
could be attributed to being familiar with CLs application so they would not be daunted to use 
them for treatment in the future. Nonetheless, the lack of knowledge and training about the 
use of CLs can put off non-users from using them in the future.  Patients were worried that CLs 
might damage their eyes. The second concern was ”will have issues applying lenses”. Studies 
have shown issues associated with lenses including bacterial infections, corneal abrasions, 
microbial keratitis and allergic sensitivity (16). As many conditions can arise due to hygienic 
issues and noncompliant behavior, CLs users were questioned in previous studies about their 
lenses use (17, 18). It has been pointed out that poor hand hygiene (11%), inadequate cleaning 
of lenses (13%) and lens storage cases (61%) were the main contributors to non-compliance 
(19). This evidence would indicate that patients may have problems associated with lenses due 
to inadequate cleaning and hygiene, which put them at possible risk of getting infections (20) 
that could damage their eye as stated in the current survey. With proper education on lens 
application and removal, majority of these complications could be avoided. Unfamiliarity and 
lack of knowledge raises worry in patients as 44% of them stated they would not use lenses for 
treatment as ”do not know enough information”. This further adds to the reason why patients 
might not be accepting the use of lenses in treatment as they do not fully understand the 
potential of this treatment. HCPs share the same concern as the patients; one major issue that 
was highlighted by the HCPs in this study was the challenges of educating patients and verbal 
counselling on drug delivering CLs in terms of safe use, compliance and hygiene. In addition, 
even HCPs require further education and training on CLs for drug delivery. Such training would 
possibly overcome the hesitancy that 58% of practitioners felt about counselling patients on 
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correct and safe CLs use. Furthermore, the results showed that nearly half of the HCPs are not 
familiar with this novel tool, which again suggests that more education and training is required.  
Few practitioners (11/112) were concerned about the difficulties that may arise by the elderly 
population in administering the medicated CLs due to manual dexterity or poor sight. 
However, CLs may suit elderly population, who find it difficult to squeeze the dropper bottle 
due to physical difficulty or rheumatoid arthritis.  The long duration of action could also tackle 
forgetfulness as a cause for non-compliance. With the right materials and techniques for 
manufacturing such as molecular imprinting, drug delivering CLs could be worn for more than 
a few days at a time. This would allow for a drastically reduced frequency of administration 
compared to eye drops.  
The other concern that practitioners linked with the use of CLs to treat ocular disease, is that 
medicated CLs would be much more expensive when compared to the price of eye drops. 
Although the price of eye drops is much cheaper than drug delivering CLs would be, the overall 
cost of non- compliance to eye drops is quite high. A study of 200 patients has already shown 
that 16% of patients had missed up to two doses of their eye drops per week (2), so this shows 
that non- compliance to eye drops is common and has subsequent negative impact. 
Furthermore, non- compliance to ocular medication can lead to progressive vision loss and 
eventually blindness (21). There is a massive financial burden due to non-compliance to 
general medication including ocular medication; the estimate cost of hospitalisation due to 
general medication non-adherence costs approximately $100-300 billion in the US per year 
(21).  Non-compliance to eye drops is well reported in literature for many reasons such as 
forgetfulness (23, 24), difficulty with administration (25), patients’ struggle to follow 
medication schedule and cost (24). By introducing medicated CLs, patient regimen adherence 
is speculated to increase leading to reduced hospitalisation, A&E visits, and reduced 
progressive worsening of ocular disease.  This in turn could reduce the financial burden. So, 
although the cost of drug delivering CLs are expected to be more expensive than eye drops, a 
greater amount of money will be saved on the long term.  Overall, a greater number of HCPs 
believe that medicated CLs have more benefits than risks and disadvantages.  
Although the study has provided a good insight into people’s acceptance of lenses and the 
reasons for and against their use, it suffers from certain limitations. As perceptions were 
examined using a questionnaire not an interview, only limited questions could be asked and 
most of the questions were multiple choice ones which could have influenced the patients’ 
answers. Patients may not have made a fully informed response due to the lack of knowledge 
on the field. Furthermore, the area where the research was conducted was populated mostly 
by white ethnic background which resulted in the majority of participants (68%)  being from 
one ethnicity which might not be representative of all patients with ocular problems. As it was 
conducted on a relatively small sample size, it would benefit from follow up interviews to 
gather more detailed feedback from patients and a larger sample size. 
Conclusion  
A majority of patients and HCPs showed acceptance of the use of CLs as part of an ocular drug 
delivery system. The main benefit related to their potential to offer long duration of action, 
hence decreasing frequency of application thus increasing regimen adherence. More than half 
of patients were open to using medicated CLs as a new treatment method especially eye drops 
users who were more prone to accept CLs. 
The main reservations were related to cost, ease of use and risk of infections. Nevertheless, 
the acceptance of use provides a driver for further research and development by both 
academics and industries. 
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Appendix 
Some of the questions used in Healthcare professionals’ questionnaire 
 
1. What is your profession? 
o Consultant Ophthalmologist  
o Consultant Ophthalmic Surgeon 
o Optometrist  
o Optician/Contact Lens Optician 
o General Practitioner  
o Hospital or Community Pharmacist  
o Other (please specify)  
2. How many years have you been working in your profession for?
o Less than 
1 year  
o 1 to 5 
years 
o 6 to 10 
years 
o More than 
10 years  
3. What are the most common eye conditions/diseases that you come across every day? More than one answer can be selected. 
□ Conjunctivitis – Allergic or Infective  
□ Blepharitis  
□ Uveitis  
□ Subconjunctival haemorrhage  
□ Glaucoma  
□ Cataracts  
□ Age-Related Macular Degeneration  
□ Other (please specify) 
4. Which current treatment method for eye conditions do you prescribe/dispense the most? Please select one answer only. 
o Eye drops  
o Eye Ointments/Creams 
o Eye Gels 
o Ocular inserts 
o Other (please specify) 
 
5. Why do you prescribe/dispense this medication/formulation the most? More than one answer can be selected. 
□ Cheapest  
□ Easy to prescribe  
 □ Patient friendly  
□ Effective  
□ High patient adherence 
□ Other (please specify) 
6. Which ocular drug treatment do you believe patients prefer in order to treat their eye conditions/diseases? Please select one 
answer only. 
o Eye drops  
o Eye Ointments/Creams 
o Eye Gels 
o Ocular inserts 
o Other (please specify) 
 
7. Why do you think patients prefer one treatment method/formulation over the others? Please select one answer only. 
o Easiest to apply  
o Convenient 
o Increased comfort 
o No/fewer side effects 
o Less frequency of administration 
o Other (please specify) 
8. What problems do you feel patients face in relation to their ocular medication? More than one answer can be selected. 
□ Recurrence of disease/ineffective medication 
□ Difficulty administering medication  
□ Patient forgetfulness in administering medication  
□ Need to administer medication multiple times a day 
□ Other (please specify) 
9. In your opinion, why do some patients need to re-visit the clinic/hospital or attend/re-attend A&E for cases relating to ocular 
diseases? Please select one answer only. 
o Non-adherence to medication  
o Ineffective medication resulting in worsening of disease 
o Misdiagnosed ocular disease  
o Other (please specify) 
10. Prior to today, have you heard of the concept of using contact lenses to deliver drugs to the eye? 
o Yes o No  
11. How did you hear about this concept? Please select one answer only. 
o Journals 
 o Internet sources 
o Word of mouth 
o Workplace  
o Have not heard of this concept before today 
12. How do you feel about the use of contact lenses as an alternative form of ocular drug delivery? Please select one answer only. 
o It is necessary  
o Current ocular drug delivery methods, like eye drops, are sufficient  
o Preferable to have another ocular treatment option for prescribers to select from based on patient needs/conditions to be 
treated 
o Other (please specify) 
13. What would you expect from this new form of ocular drug delivery? More than one answer can be selected.  
□ Longer duration of action 
□ Greater efficacy 
□ More side effects  
□ Fewer side effects  
□ More patient adherence 
□ Less patient adherence 
□ More patient preference for use 
□ Less patient preference for use 
□ Other (please specify) 
14. In your opinion, what are the benefits of using contact lenses to treat ocular diseases/conditions? More than one answer can be 
selected. 
□ Increased efficacy 
□ Reduced systemic side effects  
□ Reduced frequency of administration  
□ Increased patient adherence  
□ Other (please specify) 
15. What do you feel are the risks/challenges of using contact lenses in order to treat ocular diseases/conditions? More than one 
answer can be selected. 
□ Eye infections/inflammations  
□ Less patient adherence  
□ Challenges in counselling patients on its use 
□ Expensive when compared to conventional ocular drugs like eye drops 
Other (please specify)
 16. Would you prescribe contact lenses to treat ocular disease in patients? Give reasons for your answer.  
o Yes  o No  
 
 
Some of the questions used in assessing the Patients’ acceptance of contact lens for ocular drug delivery 
1. What treatment method have you used for your eye? (Tick all appropriate)  
 
□ Eye drops 
□ Eye ointment  
□ Eye gel  
□ Tablets  
□ Eye inserts eg ocusert 
□ Other (please specify)
 
2. What was the condition you used it for? 
□ Conjunctivitis  
□ Dry eyes 
□ Cataracts  
□ Stys 
□ Glaucoma 
□ Subconjunctival haemorrhage  
□ Inflammation post surgery 
□ Other (please specify) 
 
 
3. Did you find difficulty in applying the medication by 
yourself? 
 
□ Yes  
□ No 
 
4. How much does this effect the way you take medicine? (Scale 1-10) 
 
Low 1  2 3 4 5 6 7 8 9 10 High 
5. Do you get any eye/health issues associated with using contact lenses? 
□ Itchiness 
□ Tired eyes 
□ Blurred vision 
□ Red eyes 
□ Dry eyes 
□ Viral infections 
□ Other (please specify)
6. What is the reason you would NOT use contact lenses for drug delivery? (tick ALL appropriate)  
  
□ Worried about damaging your eye 
□ Easier to use eye drops  
□ Don’t know enough information 
□ Too hard to store and clean  
□ I have had a bad experience with contact 
lenses  
□ I will have problems with applying contact 
lenses 
□ Other (please specify
7. What method would you prefer to use? 
□ Eye drops  
□ Eye ointments 
□ Eye gels 
□ Other (please specify)  
8. Gender 
 
□ Male  □ Female  □ Not stated
9. Age  
□ 18-29 
□ 30-49 
□ 49-69 
□ 70+ 
 
10. Ethnicity  
□ White 
□ White Other 
□ Mixed 
□ Indian 
□ Pakistani 
□ Bangladeshi 
□ Other Asian 
□ Black African 
□ Black Other 
□ Chinese 
□ Any other ethnicity
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